High Mobility Group A2 gene (HMGA2), an oncofetal protein, is normally expressed in fetal development and completely shuts down in almost all organs and tissue types during adulthood. It is upregulated or overexpressed again in certain mesenchymal neoplasms due to chromosomal translocations and in malignant epithelial tumors through transcription regulation. HMGA2 overexpression can either drive tumor development or promote the aggressiveness of tumor growth. Many gynecologic neoplasms, including uterine smooth muscle tumors and ovarian cancer, are associated with HMGA2 overexpression. In this article, we review recent developments in the study of HMGA2 and its expression as a potential biomarker for gynecologic neoplasms and clinic application.

Citation of this article: Wei JJ. HMGA2: A Biomarker in Gynecologic Neoplasia. J Clin Transl Pathol 2022. doi: 10.14218/JCTP.2021.00018.

Introduction

High Mobility Group A2 gene (HMGA2), located on chromosome 12q15, was discovered as a nuclear protein that ap- pears upregulated after transformation of rat thyroid cells by retrovirus in 1985.1 Human HMGA2 consists of five exons in an over 160 kb genomic region and contains a large in- tron sequence (>140 kb) between exons 3 and 4. The ma- jor transcript of HMGA2a is a 4.1 kb mRNA that translates to a 108 amino acid HMGA2 protein. The first three exons encode three AT-hook domains, which play a very important role in transcriptional regulation. Exon 4 encodes 12 amino acids that separate the AT-hooks from the C-terminal amino acid domain, which is encoded by exon 5. The acidic tail is involved in protein-protein interaction.2

HMGA2 is overexpressed in embryonic tissue but is absent in almost all normal adult tissues and terminally differenti- ated tissues.3,4 HMGA2 overexpression in human neo- plasm was originally identified in mesenchymal tumors by positional cloning due to non-random chromosomal trans- locations at the 12q15 region.5-11 HMGA2 functions as an architectural transcription factor that can regulate multiple downstream genes. However, the role of HMGA2 in regulating the molecular pathways responsible for tumorigenesis and tumor progression is only partially understood. The on- cogenic functions of HMGA2 for neoplasia were identified through the observation of mouse models.12 Specifically, transgenic mice carrying the full-length Hmg2 gene developed pituitary adenomas,13 while transgenic mice carrying the human HMGA2 transcript under the control of an adipocyte-specific promoter developed breast fibroadenomas and salivary gland adenomas.14 Another study reported that intro- ducing HMGA2 overexpression in normal ovarian surface epithelial cells resulted in malignant transformation and tumor formation.15 Several biological processes involving HMGA2 include cell proliferation,16 stem cell self-renewal,17 cell transformation,2 epithelial-to-mesenchymal transition (EMT),18,19 tumor invasion and metastasis,20 and DNA damage repair.21 In addition, HMGA2 overexpression is associ- ated with tumor differentiation,22 unfavorable outcome, and resistance to treatment.15,23

As an oncofetal protein, HMGA2 overexpression is present in many epithelial and mesenchymal neoplasms and plays an important role in the tumorigenesis of both mes- enchymal and epithelial neoplasms. In this short review, we briefly summarize HMGA2 as a biomarker in the diagnosis and prognosis of gynecologic neoplasms.

HMGA2 in gynecologic mesenchymal tumors

HMGA2 overexpression can be seen in many mesenchymal neoplasms of the head and neck, lungs, bone, breast, and female reproductive and other organ systems.24 The uterine smooth muscle tumors and other mesenchymal neoplasms of gynecologic origin are among the tumors with charac- teristic molecular and genetic changes leading to HMGA2 overexpression.21

Uterine leiomyomas are the most common benign mes- enchymal neoplasms in the gynecologic system, and up to 70% of women will develop leiomyomas. While most leiomyomas harbor MED12 mutations,25 about 10-15% of usu- al-type leiomyomas are caused by HMGA2 overexpres- sion.26 Importantly, each leiomyoma is driven by either MED12 or HMGA2, but not by both (mutually exclusive).26 Morton’s group was first to identify HMGA2 overexpression in leiomyomas due to non-random chromosome transloca- tion and common gene rearrangement involving t (12;14) translocation.27 Interestingly, the preferential breakpoints in leiomyoma are located at the 5’UTR of HMGA2, resulting in no fusion transcript, which is different from lipomatos
neoplasms at large intron 3.24 Until recently, the association of HMGA2 with specific histologic variants of uterine smooth muscle tumor was largely unknown. Ordulu et al. observed that over 58% of intraventricular leiomyomatosis harbored HMGA2 overexpression due to gene rearrangement.28

By reviewing the selected cases of leiomyomas with HMGA2 overexpression, we noted that leiomyomas with HMGA2 overexpression exhibit subtle but distinct cytohistologic features, particularly tumor cells with small rounded and oval nuclei with increased vasculature, that differ from MED12 leiomyomas. This prompted us to investigate hydropic leiomyomas, a histologic variant of leiomyoma with the above-mentioned characteristic cytohistologic features. Hydropic leiomyomas are well-demarcated and vaguely nodular to lobulated tumors with white-grey, watery edematous cut surfaces. Microscopically, hydropic leiomyomas are edematous with increased vascularity and tumor cells arranged in nodules or cords. In a prior study, tumor cells displayed round to oval nuclei with a cord-like arrangement and perinodular growth around vessels.29 In an analysis of 24 hydropic leiomyomas, 76% showed HMGA2 overexpression by immunohistochemistry (Fig. 1). In addition, a FISH analysis with a breakpart fusion probe demonstrated at least 25% of hydropic leiomyoma had gene translocation.30

Myxoid leiomyosarcoma is a rare variant of leiomyosarcomas accounting for 10% of malignant uterine smooth muscle tumors. Diagnosis by histology alone can be made in typical cases, but most cases can be diagnostically challenging due to the bland cytology of myxoid leiomyosarcoma in typical cases, but most cases can be diagnostically challenging due to the bland cytology of myxoid leiomyosarcoma that mimics myxoid leiomyoma, myxoid endometrial stromal sarcoma, myxoid inflammatory myofibroblastic tumors, and other uterine myxoid tumors, NOS.31 Interestingly, one study found that 10 out of 10 myxoid leiomyosarcomas have HMGA2 overexpression,32 an observation that was reproducible in our study of 4 myxoid leiomyosarcomas (unpublished data). However, a target RNA sequencing analysis failed to identify HMGA2 gene rearrangement in all 15 myxoid leiomyosarcoma. Therefore, more studies are needed to compare HMGA2 expression in different mesenchymal tumors of the uterus with myxoid features. The conventional spindle cell leiomyosarcoma is considered a genomic unstable tumor with complex genomic alterations.24 In our research, we examined 51 spindle cell leiomyosarcoma and found 14% of them (7/51) were strongly immunoreactive for HMGA2;25 a similar finding was observed in leiomyomas with bizarre nuclei. Additional research is needed to further characterize the role of HMGA2 in leiomyosarcoma development and differentiation. Due to a small case number, the association of HMGA2 with clinical outcome of leiomyosarcoma remains to be established.

Fig. 1. HMGA2 expression in hydropic leiomyomas. (a) H/E stained slide of hydropic leiomyoma (10×); (b) Immunostain for HMGA2 (10×).

Aggressive angiomyxoma is a rare and clinically aggressive tumor that occurs in the soft tissues of the lower genital tract, pelvis, and perineum. Histologically, it presents as an infiltrative, hypocellular myxoid lesion with bland spindle cells with round/oval nuclei and prominent variably sized vessels. Tumors usually show an ill-defined border with local recurrence in about 30% of cases. Tumor stroma are myxoid with scattered delicate collagen fibers and broadly extend to fat, nerves, and muscle. Due to a bland histology and the aggressiveness of tumor nature, diagnosis is critical and challenging in certain cases. While most of the biomarkers for fibroblastic lesions may not contribute well to the differential diagnosis of aggressive angiomyxoma, HMGA2 is by far the most sensitive and specific marker that is overexpressed in over 90% of tumors of this type (Fig. 2).36 Therefore, HMGA2 has been broadly used as surrogate marker in evaluation of this tumor type. HMGA2 overexpression is also observed in several other mesenchymal neoplasms in gynecologic system, including lipoleiomyoma, endometrial polyyp, fibroadenoma, and adenosarcoma. Moreover, HMGA2-mediated angiogenesis plays an important role in promoting tumor growth of these mesenchymal neoplasm.37

HMGA2 in GYN epithelial malignancy

HMGA2 overexpression is common in epithelial carcinoma and is mostly caused by altered transcription regulation, rather than gene rearrangement.39 HMGA2 overexpression has been reported in many solitary carcinomas, including but not limited to colorectal, pancreatic biliary, lung, breast, head and neck, and male and female reproductive organ cancer.38 Currently, HMGA2 has been used as a biomarker for the evaluation of the aggressive tumor behavior associated with tumor growth,16 differentiation,22 unfavorable outcome, and resistance to treatment19,23

Ovarian/fallopian tube high-grade serous carcinoma is a deadly disease characterized by a short latent phase of early disease, rapid and fast tumor cell proliferation, and wide-spread disease at the time of diagnosis. Identifying the biomarkers linked to aggressive ovarian cancer may help facilitate patient care and treatment options. Malek et al. found that HMGA2 was positive in over 65% of ovarian serous carcinomas but not in normal control tissue.39 Shell et al.21 examined HMGA2 expression in 100 primary ovarian cancer cases and found that high expression of HMGA2 was significantly correlated with an adverse prognosis. In a cohort of 117 ovarian cancer cases with well-characterized clinical outcome, we found that in over 70% cases of ovar-
Wei J.: HMGA2 in gynecologic neoplasms

ian cancer, most high-grade serous carcinoma exhibited HMGA2 overexpression, and tumors with HMGA2 overexpression were significantly associated with worse clinical outcome.\(^{40,41}\) In addition, HMGA2 overexpression is also related to ascites, lymph node (LN) metastasis, and poor clinical outcome.\(^{40}\) The aggressiveness of high-grade serous carcinoma in association with HMGA2 overexpression is mostly through its regulation of epithelial mesenchymal transition.\(^{21}\) Overall, HMGA2 overexpression is very common in high-grade serous carcinoma (\(>70\%\)), followed by carcinosarcoma (65\%), but is much less common in other histologic types of ovarian cancer.\(^{41}\) For example, only 7% of low-grade endometrioid carcinomas, 23% of clear cell carcinoma, and 6% of mucinous carcinoma were found to immunoreactive for HMGA2.\(^{41}\)

Recent identification of serous tubal intraepithelial carcinoma (STIC) in the fallopian tube opens a new venue for a better understanding of the tumorigenesis of high-grade serous carcinoma. STIC demonstrates remarkable nuclear atypia along with mutant p53 immunostain patterns. To evaluate the role of HMGA2 as a surrogate biomarker for detection of this precancerous lesion, we examined HMGA2 expression in the normal epithelial cells of fallopian tubes and STIC lesions. Interestingly, HMGA2 showed to be highly overexpressed in STIC lesions, specifically in as many as 75% of STIC cases (Fig. 3), indicating an early event of HMGA2 overexpression in the tumorigenesis of high-grade serous carcinoma.\(^{42}\)

According to The Cancer Genomic Atlas (TCGA), high-grade serous carcinomas can be divided into 4 subtypes: Differentiated, Immunoreactive, Mesenchymal, and Proliferative. HMGA2 is one of the gene signatures closely associated with the Proliferative type of serous carcinoma.\(^{43}\) HMGA2 was also one of the top-ranking dysregulated genes identified by genome-wide analysis in primary human ovarian cancer.\(^{44}\) All these findings strongly suggest that HMGA2 overexpression plays an important role in high-grade serous carcinoma development and progression and, thus, can be a useful prognostic biomarker for pathology evaluation.

Uterine serous carcinoma has different histologic presentations, immunostain patterns, and molecular profiles than those of ovarian/fallopian tube serous carcinoma.\(^{45}\) Although p53 is a useful biomarker for the differential diagnosis of uterine serous carcinoma, many high-grade endometrioid carcinomas can harbor p53 mutations.\(^{45}\) In particular, one study showed that over 91\% of uterine serous carcinomas have HMGA2 overexpression.\(^{46}\) FIGO grade 3 endometrioid and serous carcinomas are considered “high-grade endometrial carcinomas,” the diagnosis of which is not highly reproducible due to the question of serous-like endometrioid carcinoma vs p53 alteration. Genomic studies on endometrial cancer consider molecular tumor classification, which separates prognostically favorable from unfavorable types of grade 3 endometrioid carcinomas. As such, combining genomic and FIGO grades has been proposed.\(^{47}\) When unavailable for genomic analysis, p53 and MSI immunostains can discriminate some, but not all, grade 3 endometrioid carcinomas. In our recently unpublished study, we found that HMGA2 overexpression is present in more than 75\% of uterine serous carcinomas and 45\% of grade 3 endometrioid carcinomas. Interestingly, none of the grade 1 endometrioid carcinomas showed HMGA2 overexpression. HMGA2 overexpression was also associated with a higher rate of lymphatic vessel invasion (LVI) and LN metastasis in grade 3 endometrioid carcinoma. This study demonstrates that HMGA2 expression is closely correlated with p53 and with the aggressive histologic features of grade 3 endometrioid carcinoma. The findings suggest that HMGA2 can be a useful marker in discriminating aggressive high-grade carcinoma from low-grade endometrioid carcinoma.

![Fig. 2. HMGA2 expression in aggressive angiomyxomas.](image)

(a) H/E stained slide of aggressive angiomyxoma (20x); (b) Immunostain for HMGA2 (40x).

![Fig. 3. HMGA2 expression in serous tubal intraepithelial carcinoma (STIC).](image)

(a) H/E stained slide of serous tubal intraepithelial carcinoma (STIC) (60x); (b) Immunostain for p53 (60x); (c) Immunostain for HMGA2 (60x).
Conclusions

HMGA2 is an oncofetal protein participating in embryogenesis and tumorigenesis that is upregulated in both epithelial and mesenchymal tissue-originated tumors. HMGA2 overexpression is correlated with distant metastasis, advanced stage tumors, and poor clinical outcome in many solitary carcinomas. As a regulator in AKT and sex-steroid hormone pathways, HMGA2 is an unique oncogene and biomarker of HMGA2 in other tumor types, grades, and differentiation. Most importantly, development of the therapeutic strategies targeting tumors with HMGA2 overexpression will help in treating many deadly neoplasms.

Acknowledgments

We thank those residents and postdoctoral fellows at Northwestern University who previously contributed to our HMGA2 studies. We particularly thank Dr. Debabrata Chakravarti for his support and scientific discussion.

Funding

This study was partially supported by the grant of NIH (PSO HD098580 to WJ).

Conflict of interest

Dr. Wei has been an editorial board member of Journal of Clinical and Translational Pathology since 2021. The author has no others to disclose.

Author contributions

Dr. Wei was the sole author of this article.

References

Wei J.: HMGA2 in gynecologic neoplasms


